Search clinical trials for: Ivt. Aflibercept (Eylea, BAY86-5321)

Total 279 results

Bayer

Completed

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina. (ANDROMEDA)

Macular Degeneration

Germany
Bayer

Completed

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice (MAIA)

Retinal Disease

Mexico
Bayer

Completed

A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema (DRAKO)

Macular Edema

United Kingdom
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

United States, Spain, Korea, Republic of, Czechia, Japan, Singapore, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Bulgaria, Portugal, Latvia, Canada, Hungary, Arge... and more
Bayer

Completed

Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice

Wet Age-related Macular Degeneration

India
Bayer

Completed

Special Drug Use Investigation of EYLEA for Diabetic Macular Edema

Macular Edema

Japan
Bayer
Regeneron Pharmaceuticals

Completed

The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting (INSIGHT)

Wet Macular Degeneration

Sweden
Bayer
Regeneron Pharmaceuticals

Terminated

A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment (XPAND)

Neovascular (Wet) Age-related Macular Degeneration

Canada, United Kingdom
Bayer

Recruiting

A Study to Collect Data on the Use of Eylea in Babies Born Too Early Who Have a Condition of the Eye Where Blood Vessels Grow Abnormally in the Retina (Retinopathy of Prematurity)

Retinopathy of Prematurity | Newborns | Infants

Japan
Bayer

Completed

Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease (XTEND)

Wet Age-related Macular Degeneration

Canada, Spain, Sweden, Belgium, Argentina, Italy, Korea, Republic of, United Kingdom, China, Denmark, France, Norway, Colombia, Australia, Ireland, Switzerland, Thailand
Bayer
Regeneron Pharmaceuticals

Completed

A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease (AURIGA)

Macular Edema

Germany, Italy, Russian Federation, Taiwan, China, Egypt, France, Kuwait, Lebanon, Saudi Arabia, United Arab Emirates
Bayer

Completed

Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO (CENTERA)

Central Retinal Vein Occlusion

France, Canada, Denmark, Germany, Italy, Spain, United Kingdom, Australia
Bayer
Regeneron Pharmaceuticals

Completed

Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion (RETRO CRVO)

Retinal Vein Occlusion

Belgium
Regeneron Pharmaceuticals
Bayer

Completed

Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration (CANDELA)

Neovascular (Wet) Age-Related Macular Degeneration

United States, Puerto Rico
Bayer
Regeneron Pharmaceuticals

Completed

Observational Study to Assess Intravitreal Aflibercept Injections Used in a "Treat and Extend" Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients (ASTERIA)

Wet Age-related Macular Degeneration

Switzerland
Bayer

Recruiting

Study to Learn More About Safety of Aflibercept Injection in Japanese Patients With Neovascular Glaucoma (NVG)

Neovascular Glaucoma

Japan
Regeneron Pharmaceuticals
Bayer

Active, not recruiting

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease (PHOTON)

Type 2 Diabetes Mellitus | Diabetic Macular Edema | Type 1 Diabetes Mellitus

United States, Puerto Rico, Japan, United Kingdom, Canada, Czechia, Germany, Hungary
Bayer

Completed

Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece (PERSEUS-GR)

Macular Degeneration | Choroidal Neovascularization

Greece
Bayer

Completed

Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME) (VIOLET)

Macular Edema

Spain, Canada, Switzerland, Portugal, Austria, Poland, Slovakia, United Kingdom, Germany, Hungary, Italy, France, Lithuania, Czechia
Bayer
Regeneron Pharmaceuticals

Completed

Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization

Choroidal Neovascularization

Japan
Bayer
Regeneron Pharmaceuticals

Completed

To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada. (PEGASUS)

Wet Macular Degeneration

Canada
Bayer
Regeneron Pharmaceuticals

Completed

EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan

Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration (PERSEUS)

Wet Age-related Macular Degeneration

Germany
Bayer
Regeneron Pharmaceuticals

Completed

Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema (APOLLON)

Diabetic Retinopathy

France
Bayer

Completed

A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD). (BELUGA)

Neovascular Age-related Macular Degeneration

Belgium
Bayer

Completed

A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America (AQUILA)

Macular Degeneration

Mexico, Argentina, Colombia, Costa Rica
Bayer

Completed

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

Macular Degeneration

Spain, Switzerland, Portugal, France, Canada, United Kingdom, Austria, Slovakia, Germany, Hungary, Italy, Lithuania, Czechia, Poland
Bayer

Completed

An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies (GALAXY)

Macular Degeneration

Germany
Bayer
Regeneron Pharmaceuticals

Completed

Study for Collection of Aflibercept Data in Routine Practice (CODEX)

Eye Diseases

France
Bayer
Regeneron Pharmaceuticals

Completed

Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO) (JPMS-CRVO)

Retinal Vein Occlusion

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada

Diabetic Macular Edema (DME) | Age-related Macular Degeneration (AMD) | Central Retinal Vein Occlusion (CRVO)

Canada
Bayer
Regeneron Pharmaceuticals

Completed

Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration (ALTAIR)

Wet Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Eylea Post Marketing Surveillance(PMS)

Macular Degeneration

Korea, Republic of
Bayer
Regeneron Pharmaceuticals

Completed

Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy (PERSEUS-IT)

Wet Macular Degeneration

Italy
Bayer
Regeneron Pharmaceuticals

Completed

Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD (RAINBOW)

Wet Macular Degeneration

France
Bayer

Completed

A Study to Learn More About How Drug Aflibercept Works in Canadian Patients With Reduced Vision Caused by New Blood Vessels Growing in the Eye (Myopic Choroidal Neovascularization or mCNV) (REALM)

Myopic Choroidal Neovascularization

Canada
Bayer
Regeneron Pharmaceuticals

Completed

EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan

Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD) (REALE)

Macular Degeneration

Spain
Bayer

Completed

Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. (AQUA)

Macular Edema

Spain, Canada, Switzerland, Portugal, Austria, Poland, Slovakia, United Kingdom, France, Czechia, Germany, Hungary, Italy, Lithuania
Bayer
RTI Health Solutions

Completed

Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept

Macular Degeneration

France, Germany, Spain, Italy, United Kingdom
Bayer
Regeneron Pharmaceuticals

Completed

Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan

Wet Macular Degeneration

Japan
Bayer
Regeneron Pharmaceuticals

Completed

Aflibercept for Retinopathy of Prematurity - Intravitreal Injection Versus Laser Therapy (FIREFLEYE)

Retinopathy of Prematurity (ROP)

Spain, Singapore, Hong Kong, Korea, Republic of, Malaysia, Japan, Taiwan, Sweden, Portugal, Belgium, Argentina, Bulgaria, Italy, Austria, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Poland, Romania, Russian Federation, Slov... and more
Bayer
Regeneron Pharmaceuticals

Completed

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye (ARIES)

Macular Degeneration

Spain, Hungary, United Kingdom, Australia, Italy, Canada, France, Germany
Bayer
Regeneron Pharmaceuticals

Completed

Study to Learn How the Drug Aflibercept Works in in Japanese Patients With Increased Eye Pressure That is Caused by New Blood Vessels Growing in the Eye (Neovascular Glaucoma or NVG). Safety of the Drug and Patients' Tolerability of the Drug Injection is Also Studied (VENERA)

Glaucoma, Neovascular

Japan
Regeneron Pharmaceuticals

Completed

Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA)

Nonproliferative Diabetic Retinopathy

United States, Germany, Hungary, Japan, Puerto Rico, United Kingdom
Centre Hospitalier Intercommunal Creteil
Bayer

Completed

Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration (ARI2)

Eye Diseases | Macular Degeneration | Retinal Degeneration | Retinal Diseases | Wet Macular Degeneration

France
Regeneron Pharmaceuticals

Completed

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection (ONYX)

Neovascular Age-Related Macular Degeneration

United States
Regeneron Pharmaceuticals
Bayer

Completed

Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema (RUBY)

Diabetic Macular Edema

United States
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Extension Study to Evaluate the Long-term Outcomes of Subjects in Study 20090 (FIREFLEYE next)

Retinopathy of Prematurity (ROP)

Spain, Korea, Republic of, Singapore, Malaysia, Japan, Taiwan, Bulgaria, Italy, Argentina, Brazil, Czechia, Greece, Hungary, Israel, Netherlands, Portugal, Romania, Russian Federation, Slovakia, Sweden, Turkey, United Kingdom, Ukraine, Belgi...

3

Subscribe